Fiche centre
The University of Texas Health Science Center at Houston
Houston — United States
Essais liés16clinical trials
VilleHoustonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06434363
Essais cliniques associés
16| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| JNJ-63733657 | Alzheimer | Phase 2 | NCT04619420 | Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | TERMINATED |
| Donanemab | Alzheimer | Phase 3 | NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | RECRUITING |
| Lorcaserin | Épilepsie | À vérifier | NCT04457687 | Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies | NO_LONGER_AVAILABLE |
| WiSE System | Insuffisance cardiaque | Non applicable | NCT02922036 | SOLVE-CRT — Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients | ACTIVE_NOT_RECRUITING |
| Tafasitamab | Lupus | Phase 1/2 | NCT06434363 | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders | RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Fenfluramine treatment (Fintepla) | Épilepsie | Phase 4 | NCT07112365 | FAST-DS — The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project | RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| VAMOS-MS — Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis | SEP | Non applicable | NCT07606742 | VAMOS-MS — Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis | RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT07217587 | EPIC — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | RECRUITING |
| BI 3000202 | Lupus | Phase 2 | NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| Implant Procedure | SEP | Non applicable | NCT06796504 | The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study | RECRUITING |
| Acupuncture intervention | Épilepsie | NA | NCT04677751 | Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment | RECRUITING |